Results 61 to 70 of about 7,461 (205)

Positive selection in the chromosome 16 VKORC1 genomic region has contributed to the variability of anticoagulant response in humans. [PDF]

PLoS ONE, 2012
VKORC1 (vitamin K epoxide reductase complex subunit 1, 16p11.2) is the main genetic determinant of human response to oral anticoagulants of antivitamin K type (AVK).
Blandine Patillon, Pierre Luisi, Hélène Blanché, Etienne Patin, Howard M Cann, Emmanuelle Génin, Audrey Sabbagh   +6 more
doaj   +1 more source

The effect of CYP2C9*2, CYP2C9*3, and VKORC1-1639 G>A polymorphism in patients under warfarin therapy in city of Kermanshah

Research in Pharmaceutical Sciences, 2018
Polymorphism in the genes encoding CYP2C9 enzyme and VKORC1 reductase significantly influence warfarin dose requirement since patients with CYP2C9*2, CYP2C9*3 and VKORC1 mutant alleles require lower warfarin maintenance doses.
Zohreh Hosseinkhani, Mona Sadeghalvad, Fathemeh Norooznezhad, Reza Khodarahmi, Mohammad Fazilati, Azadeh Mahnam, Ali Fattahi, Kamran Mansouri   +7 more
doaj   +1 more source

Clinical, manometric, genetic, and histologic associations in pediatric intestinal pseudo‐obstruction: A case series

Journal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 3, Page 660-671, March 2026.
Abstract Objectives Pediatric intestinal pseudo‐obstruction (PIPO) is a severe bowel motility disorder characterized by impaired propulsion of gastrointestinal contents without mechanical obstruction. PIPO encompasses congenital and acquired disorders, including neuropathies, myopathies, and mesenchymopathies.
Sharon Wolfson, Myra Butrviengpunt, Naomi Tjaden, Alain J. Benitez, Archana S. Kota, Jennifer Webster, Prasanna Kapavarapu, Hayat Mousa, Robert O. Heuckeroth   +8 more
wiley   +1 more source

Clinician Satisfaction With Pharmacogenomics Clinical Services at a Multistate Health System

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT Pharmacogenomics (PGx) utilizes genetic information to optimize medication management. Barriers to PGx implementation include limited confidence and knowledge in applying results, time constraints, and financial barriers. Clinical services across health systems vary greatly with differing consultative PGx service models.
Kristen Jacobsen, Natasha J. Petry, Max Weaver, Ethan Weeder, Amanda Massmann   +4 more
wiley   +1 more source

Stability of Anticoagulation Following Acenocoumarin in Stroke Patients: Role of Pharmacogenomics and Acquired Factors

Annals of Indian Academy of Neurology
Objective: Pharmacogenomics plays an important role in drug metabolism. A stable anticoagulation is important for primary and secondary prevention of cardioembolic stroke and cerebral venous sinus thrombosis (CVST). We report the role of cytochrome P450 (
Ashish Kant Dubey, Jayantee Kalita, Mohammad Firoz Nizami, Surendra Kumar, Usha Kant Misra   +4 more
doaj   +1 more source

Genetic Polymorphism Effect on Warfarin–Rifampin Interaction: A Case Report and Review of Literature

Pharmacogenomics and Personalized Medicine, 2021
Muhammad Salem,1 Islam Eljilany,2 Ahmed El-Bardissy,1 Hazem Elewa2,3 1Department of Pharmacy, Hamad General Hospital, Doha, Qatar; 2College of Pharmacy, QU Health, Qatar University, Doha, Qatar; 3Biomedical and Pharmaceutical Research Unit, QU Health ...
Salem M, Eljilany I, El-Bardissy A, Elewa H   +3 more
doaj  

Knowledge and Attitudes Regarding Pharmacogenetics of Pharmacists in the Netherlands: A National Online Survey Study

Journal of Evaluation in Clinical Practice, Volume 32, Issue 2, March 2026.
ABSTRACT Rationale, Aims and Objectives Pharmacogenetics is considered a promising method to improve pharmacotherapy, yet its implementation in clinical practice is hampered, limiting its potential benefits to the public. Previously, its uptake has been investigated within a variety of healthcare professional groups.
Emma Y. De Brabander, Nicole K. Leibold, Therese van Amelsvoort, Roos van Westrhenen, The PSY‐PGx Consortium, Kristian Kleine Schaars, Sanah Bedi, Allan H. Young, Mario Juruena, Daniel Silman, Urs Heilbronner, Monika Budde, Magnus Ingelman‐Sundberg, Marin Jukic, Martien J. H. Kas, Raj Jagesar, Ramona Moldovan, Markus M. Nöthen, Per Hoffmann, Carina M. Mathey, Alexandra Philipsen, Laura L. Kilarski, Jonathan Laatsch, Noam Shomron, Erik Van der Eycken, Nigel Olisa, Eduard Vieta, Natalia E. Fares‐Otero, Thomas G. Schulze, Therese van Amelsvoort, Bea Campforts, Emma de Brabander, Moritz J. Rossner, Sven P. Wichert, Roos van Westrhenen   +34 more
wiley   +1 more source

Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting [PDF]

, 2016
This manuscript provides nomenclature recommendations developed by an international workgroup to increase transparency and standardization of pharmacogenetic (PGx) result reporting. Presently, sequence variants identified by PGx tests are described using
Agúndez, José A.G., Appell, Malin Lindqvist, Bell, Gillian C., Black, John Logan, Boukouvala, Sotiria, Bruckner, Carsten, Bruckner, Carsten, Bruford, Elspeth, Caudle, Kelly, Coulthard, Sally, Daly, Ann K., Del Tredici, Andria L., den Dunnen, Johan T, Drozda, Katarzyna, Everts, Robin, Flockhart, David, Freimuth, Robert, Gaedigk, Andrea, Hachad, Houda, Hartshorne, Toinette, Ingelman-Sundberg, Magnus, Kalman, Lisa V., Klein, Teri E., Lauschke, Volker M., Maglott, Donna R., McLeod, Howard L., McMillin, Gwendolyn A., Meyer, Urs A., Müller, Daniel J., Nickerson, Deborah A., Oetting, William S., Pacanowski, Michael, Pratt, Victoria M., Relling, Mary V., Roberts, Ali, Rubinstein, Wendy S., Sangkuhl, Katrin, Schwab, Matthias, Scott, Stuart A., Sim, Sarah C, Thirumaran, Ranjit K, Toji, Lorraine H., Tyndale, Rachel, van Schaik, Ron HN, Whirl-Carrillo, Michelle, Yeo, Kiang-Teck J, Zanger, Ulrich M.   +46 more
core   +1 more source

Hypoxia in the Initiation and Progression of Neuroblastoma Tumours [PDF]

, 2020
Neuroblastoma is the most frequent extracranial solid tumour in children, causing 10% of all paediatric oncology deaths. It arises in the embryonic neural crest due to an uncontrolled behaviour of sympathetic nervous system progenitors, giving rise to ...
Gómez Muñoz, María Ángeles, Huertas Castaño, Carlos, Pardal Redondo, Ricardo, Vega Moreno, Francisco Manuel   +3 more
core   +1 more source

Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5‐year perspective from an EQA provider

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 445-456, February 2026.
Aims Pharmacogenetic implementation requires awareness of the state‐of‐the‐art practice of laboratories providing pharmacogenetic testing. This study investigated how pharmacogenetic guidelines and recommendations have been implemented over time by Italian laboratories participating in the external quality assessment (EQA) Pharmaco‐scheme established ...
Rossana Roncato, Samantha Perfler, Diletta Pasin, Elena Peruzzi, Michael Woodcock, Henry Thomas, Rebecca Goodall, Simon J. Patton, Erika Cecchin   +8 more
wiley   +1 more source